Where Have the Dead Gone?

Where Have the Dead Gone?

Bibliographic Details
Main Authors:	Michael Günther, Falk Mörl, Robert Rockenfeller
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-03-01
Series:	Frontiers in Medicine
Subjects:	pivotal clinical trial SARS-CoV-2 mortality prognosis vaccine
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.837287/full

Similar Items

Corrigendum: Where have the dead gone?
by: Michael Günther, et al.
Published: (2023-10-01)

Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval
by: Ebenezer Tumban
Published: (2020-12-01)

Platforms Exploited for SARS-CoV-2 Vaccine Development
by: Shilu Mathew, et al.
Published: (2020-12-01)

Contribution to pathogenesis of accessory proteins of deadly human coronaviruses
by: Jesus Hurtado-Tamayo, et al.
Published: (2023-05-01)

Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks
by: Ralf Wagner, et al.
Published: (2021-07-01)

SARS-CoV-2 virus: Vaccines in development
by: Qingrui Huang, et al.
Published: (2021-03-01)

Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2
by: Ilir Alimehmeti
Published: (2021-01-01)

A randomized, double‐blind, placebo‐controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS‐CoV‐2 vaccine SCoK in adults
by: Deyan Luo, et al.
Published: (2022-09-01)

Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies
by: Chris Wynne, et al.
Published: (2023-12-01)

Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial
by: Aleksandr V. Kudriavtsev, et al.
Published: (2023-02-01)

The biological diversity of coronaviruses: where will the new threat come from?
by: Alexandr Khaitovich, et al.
Published: (2022-05-01)

COVID19 biomarkers: What did we learn from systematic reviews?
by: Sabina Semiz
Published: (2022-12-01)

Evaluating enrollment and representation in COVID-19 and HIV vaccine clinical trials
by: Daisy Lezo Ramirez, et al.
Published: (2024-07-01)

Characterization of Individuals Interested in Participating in a Phase I SARS-CoV-2 Vaccine Trial
by: Parichehr Shamsrizi, et al.
Published: (2021-10-01)

An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era
by: Alejandro Pascual-Iglesias, et al.
Published: (2021-08-01)

The Vaccine World of COVID-19: India’s Contribution
by: Vivek P. Chavda, et al.
Published: (2022-11-01)

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trialResearch in context
by: Yu-Zhou Gui, et al.
Published: (2023-05-01)

Potential treatments of COVID-19: Drug repurposing and therapeutic interventions
by: Pawan Kumar Raghav, et al.
Published: (2023-05-01)

Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)
by: Francisco Hernández-Bernal, et al.
Published: (2022-04-01)

Therapeutic Role of Neutralizing Antibody for the Treatment against SARS-CoV-2 and Its Emerging Variants: A Clinical and Pre-Clinical Perspective
by: Manojit Bhattacharya, et al.
Published: (2022-09-01)

Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-Year follow-up: phase I and II clinical trial final result
by: Jonny Jonny, et al.
Published: (2023-06-01)

Viral Vectors for COVID-19 Vaccine Development
by: Kenneth Lundstrom
Published: (2021-02-01)

RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement
by: Hana M. Abdelzaher, et al.
Published: (2021-10-01)

Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
by: Ahmed A. Al-Karmalawy, et al.
Published: (2021-11-01)

A Multi-Center, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland—First Results
by: Hanna Czajka, et al.
Published: (2022-02-01)

A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Impact of BCG Re-Vaccination on the Incidence and Severity of SARS-CoV-2 Infections among Symptomatic Healthcare Professionals during the COVID-19 Pandemic in Poland—Evaluation of Antibody Concentrations
by: Paweł Zapolnik, et al.
Published: (2022-12-01)

Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years
by: Fatemeh Gholami, et al.
Published: (2023-02-01)

COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2Research in context
by: Alex J. Szubert, et al.
Published: (2023-02-01)

Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines
by: Hsin-I Shih, et al.
Published: (2020-08-01)

A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic
by: Colin D. Funk, et al.
Published: (2020-06-01)

SARS-CoV-2 vaccines, where do we stand?
by: Fischer, Alain
Published: (2021-01-01)

Epidemiology, clinical and biological characteristics, and prognosis of critically ill COVID 19 patients: a single-center experience through 4 successive waves
by: Sonia Tchakerian, et al.
Published: (2024-11-01)

Mortality and functional outcomes 18 months after hospitalization for COVID-19 in geriatric patients: a multicentric cohort study
by: Marion Claes, et al.
Published: (2024-09-01)

Association of Echocardiographic Findings with in-Hospital Mortality of COVID-19 Patients and Their Changes in One-Month Follow-Up; a Cohort Study
by: Seyed Morsal Mosallami Aghili, et al.
Published: (2022-10-01)

Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
by: Sicong Yu, et al.
Published: (2021-06-01)

Human Coronavirus Spike Protein Based Multi-Epitope Vaccine against COVID-19 and Potential Future Zoonotic Coronaviruses by Using Immunoinformatic Approaches
by: Zulqarnain Baloch, et al.
Published: (2022-07-01)

Potential Immunogenic Activity of Computationally Designed mRNA- and Peptide-Based Prophylactic Vaccines against MERS, SARS-CoV, and SARS-CoV-2: A Reverse Vaccinology Approach
by: Taimoor Khan, et al.
Published: (2022-04-01)

Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight
by: Chunting He, et al.
Published: (2020-07-01)

Reduction in severity and mortality in COVID-19 patients owing to heterologous third and fourth-dose vaccines during the periods of delta and omicron predominance in Thailand
by: Kannikar Intawong, et al.
Published: (2023-01-01)

COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street?
by: Kenneth Lundstrom, et al.
Published: (2021-07-01)